ABOUT
ALS | Costa
ALS | COSTA helps innovative healthcare companies establish, introduce, and expand highly specialized oncology, nuclear medicine, radiopharmaceutical, and interventional medical technologies across Brazil and Latin America. As a boutique strategic advisory firm led by Ana Lúcia Costa, it serves as an in-country strategic partner for companies navigating some of the world’s most complex and highly regulated healthcare markets, combining senior strategic advisory with hands-on execution across regulatory navigation, clinical adoption, and commercialization.
The firm’s expertise is built on more than 11 years leading the introduction, clinical implementation, and market development of Selective Internal Radiation Therapy (SIRT, or radioembolization), alongside broader advancement of nuclear medicine technologies across the region. In that time, ALS | COSTA activated 37 SIRT treatment centers — establishing the clinical infrastructure that today performs virtually all radioembolization procedures in Brazil, consistently achieving first clinical cases within 1–2 months of engagement and supporting sustainable annual in-market revenues of USD 4–6 million.
Serving as an extension of its clients’ leadership team in the region, ALS | COSTA provides end-to-end support across the full technology lifecycle — from market opportunity assessment and regulatory and reimbursement strategy to stakeholder engagement, logistics orchestration, and long-term market development, reducing execution risk and ensuring breakthrough healthcare technologies are introduced with rigor, precision, and lasting sustainability.
ALS | Costa
ALS | Costa is a boutique strategic advisory firm specializing in the identification, introduction, and implementation of high-impact, niche medical technologies in complex and highly regulated healthcare markets. Led by Ana Lúcia Santos Costa, ALS | Costa acts as an in-country strategic partner for medical technology companies, supporting them from opportunity assessment through full market execution.
With hands-on experience in innovative and oncologic therapies — including over a decade dedicated to the introduction and development of highly specialized interventional oncology treatments across Brazil and Latin America, with involvement in the early stages of adoption and clinical integration of complex treatment approaches in the region — the firm delivers end-to-end support encompassing regulatory strategy, clinical implementation, stakeholder engagement, logistics orchestration, and early commercialization.
Operating as the client’s eyes, judgment, and strategic presence on the ground, ALS | Costa ensures that breakthrough technologies are introduced in Brazil and Latin America with rigor, precision, and long-term sustainability.